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Background: Real-world prescription pathways leading to triple therapy (TT) (inhaled 
corticosteroid [ICS] plus long-acting β
2
-agonist bronchodilator [LABA] plus long-acting mus-
carinic antagonist) differ from Global initiative for chronic Obstructive Lung Disease [GOLD] 
and National Institute for Health and Care Excellence treatment recommendations. This study 
sets out to identify COPD patients without asthma receiving TT, and determine the pathways 
taken from diagnosis to the first prescription of TT.
Methods: This was a historical analysis of COPD patients without asthma from the Optimum 
Patient Care Research Database (387 primary-care practices across the UK) from 2002 to 2010. 
Patient disease severity was classified using GOLD 2013 criteria. Data were analyzed to deter-
mine prescribing of TT before, at, and after COPD diagnosis; the average time taken to receive 
TT; and the impact of lung function grade, modified Medical Research Council dyspnea score, 
and exacerbation history on the pathway to TT.
Results: During the study period, 32% of patients received TT. Of these, 19%, 28%, 37%, 
and 46% of patients classified as GOLD A, B, C, and D, respectively, progressed to TT after 
diagnosis (P,0.001). Of all patients prescribed TT, 25% were prescribed TT within 1 year 
of diagnosis, irrespective of GOLD classification (P=0.065). The most common prescription 
pathway to TT was LABA plus ICS. It was observed that exacerbation history did influence 
the pathway of LABA plus ICS to TT.
Conclusion: Real life UK prescription data demonstrates the inappropriate prescribing of TT 
and confirms that starting patients on ICS plus LABA results in the inevitable drift to overuse 
of TT. This study highlights the need for dissemination and implementation of COPD guidelines 
to physicians, ensuring that patients receive the recommended therapy.
Keywords: chronic obstructive pulmonary disease, GOLD guidelines, observational study, 
prescribing patterns, primary care
Introduction
Chronic obstructive pulmonary disease (COPD) contributes significantly to health care 
costs worldwide.1 While there is no cure for COPD, it is preventable and treatable 
by reducing and relieving the impact of symptoms, such as chronic cough, chronic 
sputum production, and dyspnea while also reducing the risk of exacerbations.2 The 
current Global initiative for chronic Obstructive Lung Disease (GOLD) strategy 
classifies COPD patients, according to an assessment of lung function (spirometry), 
current symptoms, and future exacerbation risks, into one of four groups: GOLD A, 
B, C, and D.2
The GOLD 2015 strategy document also proposes suitable first and secondary 
choice pharmacologic therapies for each of these groups.2 Specifically, the prescribing 
of triple therapy (TT), designated as long-acting β
2
-agonist bronchodilator (LABA) 
with a long-acting muscarinic antagonist (LAMA) and an inhaled corticosteroid 
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(ICS), is recommended exclusively for COPD patients in 
group D (forced expiratory volume in 1 second [FEV
1
],50% 
predicted and/or a history of two or more exacerbations per 
year; or one or more hospitalizations for a COPD exacerba-
tion according to the GOLD 2013 update3 and a modified 
Medical Research Council [mMRC] grade 2; or a COPD 
assessment test score 10; or a clinical COPD questionnaire 
1). Similarly the National Institute for Health and Clinical 
Excellence (NICE) in the UK has created an algorithm for 
prescribing inhaled pharmacotherapies based on a multi-
dimensional assessment of COPD patients.4 Despite these 
guidelines, real-world studies indicate that pharmacological 
treatments often differ from the recommendations.5–8 To date, 
studies have indicated that there is insufficient evidence to 
determine whether TT is clinically superior to dual therapy 
options9,10 and that there is a requirement for longer-term 
studies to assess the value of this therapy.11 NICE guidelines 
state that the use of TT is only cost-effective in patients with 
a predicted FEV
1
,50% and who are frequent exacerbators 
(two or more exacerbations in the past 12 months),4 thereby 
the overuse of TT is probably wasteful of limited health 
care resources when probably only LAMA, LABA, or dual 
bronchodilator (LABA plus LAMA) is required.
The use of TT exposes patients to the long-term use of 
ICS, which is already reported to be widely used in patients 
with GOLD A and B where it is not clinically indicated.5,6,12–17 
Early studies have shown that patients with more severe 
COPD and who have a history of frequent exacerbations 
were most likely to benefit from ICS treatment.18–20 However, 
recent studies have shown the overuse of ICS in COPD 
patients with mild to moderate disease21 which is contrary 
to current GOLD recommendations and to the approved 
COPD indications for ICS in combination with LABAs. 
NICE guidelines also indicate that ICS, in combination 
with a LABA, is not cost-effective in COPD patients with a 
predicted FEV
1
50%.4 The inappropriate use of ICS results 
in these patients being exposed early in the disease to the 
known side effects associated with ICS,22–25 in particular 
pneumonia.26–28 Furthermore, ICS use does not necessarily 
result in superior efficacy when compared to other treat-
ment options10,21,29–31 or decrease hospitalizations in COPD 
patients.32
In order to suggest solutions for how alignment with 
recommendations could be improved, it is necessary to 
understand what treatment decisions are being made by 
general practitioners and how they evolve over time and lead 
to TT being prescribed. This historical, observational study 
sets out to understand prescribing practices by using COPD 
patient data from a large UK patient dataset, Optimum Patient 
Care Research Database (OPCRD). The aims of this study 
were to explore the prescribing pathways to TT; specifically, 
what patients were prescribed prediagnosis and at the time of 
diagnosis and what they changed to over time. Furthermore, 
the aim was to identify the most common treatment pathways 
to TT and evaluate what influenced these pathways to TT.
Methods
Data source
The study utilized data from the OPCRD which is a quality-
controlled longitudinal primary-care database mainly con-
taining respiratory data. At the time of data extraction for 
this study, the OPCRD comprised anonymous patient data 
from 387 primary-care practices across the UK serving a 
population of over 3 million patients, of which data from 318 
primary-care practices were utilized for this study.33
The first type of data consisted of routine clinical data 
where Optimum Patient Care software interfaced with 
primary-care practice management systems to extract 
information which included patient demographics, standard 
COPD comorbidities, exacerbation history, mMRC dyspnea 
score, and current therapy.
The second type of data collected was on patient-reported 
outcomes in a subset of patients. Eligible patients with 
respiratory disease (those with diagnoses and/or in receipt 
of prescriptions for COPD and approved for participation 
by their general practitioner) completed validated disease-
assessment questionnaires, which contained questions to 
calculate mMRC scores.
All data in the OPCRD is anonymized. This database has 
been approved by Trent Multi Centre Research Ethics Com-
mittee for clinical research use, and the OPCRD’s indepen-
dent Anonymized Data Ethics Protocols and Transparency 
committee verified and approved the planned analysis.33 This 
study is registered at www.clinicaltrials.gov with identifier 
number NCT01786720.
study design and patients
A historical cohort study design was utilized in this study, 
which contained data from 1997–2010. The analyses utilized 
data from 2002–2010. Data prior to 2002 was excluded to 
ensure the full analysis of treatment pathways including a 
LAMA treatment, tiotropium, which was approved in the 
UK in 2002.34
The analysis included patients $40 years of age at ini-
tial date of COPD diagnosis (quality outcome framework 
diagnostic code35), with spirometry data supportive of a 
COPD diagnosis (FEV
1
/forced vital capacity ,0.7) in the 
5 years prior to and inclusive of the date of diagnosis, and 
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having data 1 year prior to and a minimum of 2 years post-
initial date of diagnosis.
The pathway to TT was examined over time from patients 
with an initial date of COPD diagnosis from the years 
2002–2010. GOLD 2013 group classification was utilized in 
this study and was based on COPD symptoms (mMRC), spiro-
metric classification, and number of exacerbations.3 Other 
exclusion criteria consisted of: patients whose initial date of 
COPD diagnosis was before 2002 (due to UK approval of 
tiotropium in 200234); patients who had an asthma diagnosis; 
and patients with unknown GOLD classification (Figure 1).
COPD initial therapy was defined as pharmacological 
therapy prescribed during 1 year prior to and at the ini-
tial date of COPD diagnosis (baseline period). Therapies 
were grouped into four categories: no TT prescription, TT 
prescribed prior to initial date of COPD diagnosis, TT pre-
scribed at initial date of COPD diagnosis, and TT prescribed 
after initial date of COPD diagnosis.
analysis of data
Summaries were produced for all characteristics at the time 
of diagnosis. Data were analyzed for the number of patients 
who were and were not prescribed TT prior to, at, and after 
COPD diagnosis. For patients who were prescribed TT after 
COPD diagnosis, the time taken for these patients to receive 
TT was categorized into years: up to 1 year, 1–2 years, 
2–3 years, 3–4 years, 4–5 years, 5–6 years, 6–7 years, 
7–8 years, 8–9 years, 9–10 years, and 10 years.
&23'SDWLHQWVQ 
23&5'SDWLHQWVIURPSUDFWLFHVLQWKHVWXG\Q 
,QFOXVLRQFULWHULD ([FOXVLRQFULWHULD
&23'GLDJQRVLVXVLQJ42)UHDGFRGHV
2QH\HDURISUDFWLFHGDWDSULRUWR&23'GLDJQRVLVDQG\HDUVRISUDFWLFHGDWDSRVW&23'GLDJQRVLV
6SLURPHWU\GDWDVXSSRUWLYHRI&23'GLDJQRVLVLQ\HDUZLQGRZDURXQGWKHGDWHRIGLDJQRVLV
&23'GLDJQRVLVZLWKLQWKHODVW\HDUV
,QDGHTXDWHEDVHOLQHRURXWFRPHGDWDQ 
$JHG\HDUVDWGLDJQRVLVQ 
1RYDOLGVSLURPHWU\GDWDQ 
'LDJQRVHGHDUOLHUWKDQQ 
±±FRKRUW Q ±$VWKPDGLDJQRVLV Q ±8QNQRZQ*2/'JURXS Q 
5HJLVWHUHGDWSUDFWLFHQ 
$JHG\HDUVDWGLDJQRVLVQ 
'LDJQRVLVVXSSRUWHGE\VSLURPHWU\Q 
'LDJQRVLVIURPRQZDUGVQ 
1RQDVWKPD&23'SDWLHQWVEDVHGRQ±FRKRUWDQGNQRZQ*2/'JURXSLQJQ 
Figure 1 Patient selection.
Abbreviations: gOlD, global initiative for chronic Obstructive lung Disease; OPCrD, Optimum Patient Care research Database; QOF, quality and outcomes 
framework.
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Common treatment pathways were identified based on 
a number of patients $1% of the total study population fol-
lowing a particular pathway. Pathways followed by ,1% 
of patients were grouped together and presented as other 
non-frequent pathways. Treatment pathways were mapped 
from the initial therapy (defined as the sum of therapies 
prescribed during 1 year prior to and at the initial date of 
COPD diagnosis) to the first prescription of TT.
Lung function grade, mMRC, and exacerbation history 
were calculated during 1 year prior to and at the initial date 
of COPD diagnosis. The impact of lung function grade, 
mMRC score (dyspnea), and exacerbation history at baseline 
on treatment pathways and treatment pathways to TT was 
also described.
Statistical differences between the patients split into 
cohorts was calculated for those who were: 1) not prescribed 
TT; 2) prescribed TT prior to the initial date of COPD 
diagnosis; 3) prescribed TT on the date of COPD diagnosis; 
and 4) prescribed TT after the date of COPD diagnosis. 
A chi-square test was used to compare whether all groups 
analyzed were statistically different (the P-value applies to 
all groups being compared).
Results
Patient selection
Of the 42,704 patients diagnosed with COPD between 
2002 and 2010, 11,858 subjects met the eligibility criteria 
(Figure 1). Subsequent analyses were carried out on this 
cohort of patients.
Patient characteristics and demographics
A summary of all eligible patient characteristics at time 
of diagnosis is provided in Table 1. The median age of 
patients was 66 years with an interquartile range from 
60 to 74 years. The proportion of males was 54%. Most 
patients were ex-smokers (50%) or current smokers (47%). 
In the year preceding the study, 67% of patients did not 
experience an exacerbation, 19% of patients experienced 
one exacerbation, and 14% experienced two or more 
exacerbations. COPD diagnosis, according to GOLD 2013 
lung function grade,3 classified 70% of patients as having 
mild-to-moderate airflow limitation (FEV
1
$50%), while 
25% and 5% of patients had severe and very severe air-
flow limitation, respectively. At the closest date to initial 
date of COPD diagnosis, eligible patients were classified 
according to GOLD 2013 as 41% (n=4,822) as GOLD A, 
25% (n=2,933) as B, 17% (n=2,055) as C, and 17% as 
D (n=1,988) (Table 1).
TT status and progression to TT in 
COPD patients
Regardless of GOLD category, 32% of patients received 
TT during the study period (Table 2). A small proportion of 
GOLD A, B, and C patients received TT prior to their initial 
recorded COPD diagnosis (1%, 1%, and 2%, respectively) 
(Table 2). A similar percentage of GOLD A, B, and C patients 
were prescribed TT at initial diagnosis or within 1 year (1%, 
1%, and 2%, respectively) (Table 2). However, after initial 
COPD diagnosis, many GOLD A, B, and C patients (19%, 
28%, and 37%, respectively; P,0.001) were prescribed TT 
(Table 2).
Analysis of the time to TT demonstrated that 25% of 
patients who progressed to TT did so within 1 year after 
diagnosis (GOLD A: 26%; GOLD B: 22%; GOLD C: 24%; 
and GOLD D: 28%; P=0.065) (Figure 2). Within 2 years of 
Table 1 summary of patient characteristics at time of diagnosis
Total population
N=11,858 (100%)
age, years
Median (IQr) 66 (60–74)
sex, n (%)
Male 6,383 (53.8)
BMI
Median (IQr) 26.5 (23–30)
smoking status, n (%)
Current smoker 5,539 (46.7)
ex-smoker 5,893 (49.7)
nonsmoker 424 (3.6)
number of severe exacerbations during the year prior to and including 
the initial date of COPD diagnosis, n (%)
0 7,913 (66.7)
1 2,300 (19.4)
2 853 (7.2)
$3 792 (6.7)
lung function, gOlD grade, n (%)
Mild (FeV1$80% predicted) 1,674 (14.1)
Moderate (50%#FeV1 ,80% predicted) 6,666 (56.2)
severe (30%# FeV1 ,50% predicted) 2,956 (24.9)
Very severe (FeV1,30% predicted) 562 (4.7)
mMrC score, n (%)
0–1 6,937 (58.5)
2+ 4,921 (41.5)
GOLD 2013 classification,* n (%)
gOlD a (low risk, less symptoms) 4,882 (41)
gOlD B (low risk, more symptoms) 2,933 (25)
gOlD C (high risk, less symptoms) 2,055 (17)
gOlD D (high risk, more symptoms) 1,988 (17)
Note: *GOLD group recorded closet to initial diagnosis, based on GOLD 2013 
(a, B, C, and D).
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary 
disease; FeV1, forced expiratory volume in 1 second; gOlD, global initiative for 
chronic Obstructive Lung Disease; IQR, interquartile range; mMRC, modified 
Medical research Council.
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initial diagnosis, 40% of patients progressed to TT (GOLD 
A: 46%; GOLD B: 39%; GOLD C: 42%; and GOLD D: 47%; 
Figure 2), with 50% of patients progressing to TT within 
3 years after diagnosis (GOLD A: 62%; GOLD B: 57%; 
GOLD C: 60%; and GOLD D: 64%; P=0.065) (Figure 2). 
Almost 100% of patients who progressed to TT in GOLD 
A, B, C, and D did so within 8 years after initial diagnosis 
(Figure 2).
Therapy pathway to TT
A total of 86 treatment pathways were identified in the COPD 
population (n=3,505). Among these, 17 frequent treatment 
pathways were identified (n=2,970) (Figure 3). The most 
frequent treatment pathway was ICS plus LABA → ICS 
plus LABA plus LAMA (n=869 [25%]) (Figure 3). The 
second and third most frequent treatment pathways to 
TT were patients who were prescribed TT as their initial 
therapy (ICS plus LABA plus LAMA) and ICS → ICS plus 
LABA → ICS plus LABA plus LAMA (n=341 [10%] and 
n=310 [9%], respectively). Approximately 15% (n=535) 
of patients were prescribed inhaled therapy according to 
treatment pathways with ,1% frequency overall (other non-
frequent pathways).
The impact of mMRC score (dyspnea) revealed that, in 
patients with a mMRC score of 4, 25% of this group fol-
lowed the most common pathway to TT (ICS plus LABA → 
ICS plus LABA plus LAMA) (Table 3). In patients with a 
mMRC score of 0, 1, 2, and 3, approximately 24% took the 
most common treatment pathway (ICS plus LABA → ICS 
plus LABA plus LAMA). A similar trend was observed for 
the other 16 most frequent treatment pathways.
The impact of the number of exacerbations at baseline 
on the most common treatment pathways was also analyzed 
(Table 4). Of patients who experienced three or more exac-
erbations, 43% followed the pathway of ICS plus LABA → 
ICS plus LABA plus LAMA. The percentage of patients 
with two, one, or no history of exacerbations following this 
pathway was 33%, 26%, and 20%, respectively. A similar 
trend was observed for the remaining treatment pathways.
A similar percentage of patients in each of the GOLD 
2013 lung function grades followed the most common path-
way, ICS plus LABA → ICS plus LABA plus LAMA (grade 
1=25%, grade 2=24%, grade 3=26%, and grade 4=23%) 
(Table 5). A similar trend was observed for the other 16 
possible treatment pathways.
Discussion
In this study, an analysis of the pathways leading to TT indi-
cated that one-third of COPD patients with no concomitant 
asthma diagnosis between 2002 and 2010 progressed to TT. 
Results demonstrated that TT was inappropriately used in 
GOLD A, B, and C patients. Approximately 25% of all 
patients prescribed TT received their first TT prescription 
1 year after diagnosis, rising to 50% within 3 years post 
diagnosis, and eventually resulting in 100% 8 years postdi-
agnosis. The most common pathway to TT observed was ICS 
plus LABA pre-COPD diagnosis followed by TT postdiag-
nosis of COPD (ICS plus LABA → ICS plus LABA plus 
LAMA). The mMRC dyspnea score and impairment in lung 




   ± ± ± ± ± ± ± ± ± !7LPHDIWHUGLDJQRVLV\HDUV
S
DWLH
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*2/'$*2/'%*2/'&*2/''
Figure 2 Cumulative proportion of patients receiving triple therapy by gOlD 
group (2002–2010).
Note: P=0.065 (chi-square test).
Abbreviation: gOlD, global initiative for chronic Obstructive lung Disease.
Table 2 Triple therapy status by gOlD group (2002–2010)
GOLD group Total n (%)
A B C D
no triple therapy prescription 3,864 (79) 2,052 (70) 1,210 (59) 977 (49) 8,103 (68)
Triple therapy prescribed prior to initial diagnosis 47 (1) 41 (1) 49 (2) 42 (2) 179 (2)
Triple therapy prescribed at initial diagnosis 46 (1) 30 (1) 39 (2) 47 (2) 162 (1)
Triple therapy prescribed after initial diagnosis 925 (19) 810 (28) 757 (37) 922 (46) 3,414 (29)
Total n (%) 4,882 (100) 2,933 (100) 2,055 (100) 1,988 (100) 11,858 (100)
Note: P,0.001 (chi-square test).
Abbreviation: gOlD, global initiative for chronic Obstructive lung Disease.
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Figure 3 Distribution of different treatment pathways leading to triple therapy (ICS plus LABA plus LAMA), identified from total triple therapy population (n=3,505).
Notes: Pathways with a percent frequency of less than 1% were grouped under the category “other non-frequent pathways”. The first drug listing in the treatment pathway 
was considered to be the patient’s initial therapy, and the second drug listing was the prescription after the initial date of COPD diagnosis.
Abbreviations: ICs, inhaled corticosteroid; laBa, long-acting β2-agonist; laMa, long-acting muscarinic antagonist; saBa, short-acting β2-agonist; saMa, short-acting 
muscarinic antagonist.
function were not evaluating factors that influenced pathways 
leading to TT; however, the number of exacerbations was 
shown to influence this progression from ICS plus LABA 
to TT. Throughout all the common pathways to TT (1% 
frequency) identified, the use dual bronchodilators (LABA 
plus LAMA) as a therapy option was not observed.
NICE guidelines suggest that patients with persistent 
breathlessness and exacerbations should progress to TT,4 
with GOLD indicating the use of TT in GOLD D patients.2 
Results from this study demonstrated that approximately 
one-third of all COPD patients in this study were receiv-
ing TT, which falls in the range observed in similar studies 
that were conducted in Japan (21%),36 France (33%),37 and 
Greece (44.8%).38 Of the patients prescribed TT in the study 
presented here, 19%, 28%, and 37% of GOLD A, B, and C 
patients, respectively, were prescribed TT after their initial 
diagnosis of COPD. The frequency of TT being prescribed is 
comparable to that observed from other studies. In a French 
study, the percentage of GOLD A, B, C, and D patients being 
prescribed TT was 20%, 32%, 25%, and 48%, respectively.37 
A study by Miyazaki et al36 also observed similar rates of 
TT being prescribed to GOLD B, C, and D with slightly 
less TT prescribed to GOLD A patients (9%). Similarly, in 
a Canadian study, 20% and 30% of GOLD A and GOLD B 
patients, respectively, were prescribed TT.39 Overall, this 
indicates that the prescription behaviors observed in this UK 
study do not differ from those reported by other countries. 
A study by Corrado et al14 suggested that some respiratory 
specialists prefer to use TT even in patients who do not 
have severe COPD. This was evident in the present study, 
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Table 3 Pathways to triple therapy split by mMrC score
Treatment pathway from date of COPD diagnosis mMRC score
0
n (%)
1
n (%)
2
n (%)
3
n (%)
4
n (%)
ICs + laBa → ICs + laBa + laMa 59 (24) 347 (23) 231 (25) 182 (29) 50 (25)
ICs + laBa + laMa 25 (10) 156 (11) 90 (10) 48 (8) 22 (11)
ICs → ICs + laBa → ICs + laBa + laMa 20 (8) 131 (9) 79 (8) 60 (10) 20 (10)
none → ICs + laBa → ICs + laBa + laMa 23 (9) 96 (7) 78 (8) 55 (9) 16 (8)
saBa → ICs + laBa → ICs + laBa + laMa 9 (3.6) 78 (5) 43 (4.6) 26 (4.1) 5 (2.5)
none → ICs + laBa + laMa 11 (4.4) 66 (4.4) 33 (3.5) 31 (4.9) 9 (4.5)
none → laMa → ICs + laBa + laMa 15 (6) 63 (4.2) 39 (4.2) 27 (4.3) 3 (1.5)
none → ICs → ICs + laBa → ICs + laBa + laMa 9 (3.6) 52 (3.5) 36 (3.8) 16 (2.5) 5 (2.5)
laMa → ICs + laBa + laMa 7 (2.8) 58 (3.9) 25 (2.7) 13 (2.1) 4 (2.0)
saBa → ICs → ICs + laBa → ICs + laBa + laMa 6 (2.4) 34 (2.3) 28 (3.0) 16 (2.5) 7 (3.5)
saBa + saMa → ICs + laBa → ICs + laBa + laMa 2 (0.8) 42 (2.8) 21 (2.2) 16 (2.5) 9 (4.5)
saBa → laMa → ICs + laBa + laMa 10 (4.0) 28 (1.9) 26 (2.8) 9 (1.4) 4 (2.0)
ICs → ICs + laMa → ICs + laBa + laMa 2 (0.8) 25 (1.7) 18 (1.9) 15 (2.4) 6 (3.0)
ICs → ICs + laBa + laMa 7 (2.8) 28 (1.9) 8 (0.9) 4 (0.6) 3 (1.5)
ICs + laMa → ICs + laBa + laMa 0 (0) 27 (1.8) 14 (1.5) 5 (0.8) 1 (0.5)
laBa → ICs + laBa → ICs + laBa + laMa 4 (1.6) 15 (1.0) 7 (0.7) 12 (1.9) 2 (1.0)
none → laBa → ICs + laBa → ICs + laBa + laMa 1 (0.4) 16 (1.1) 10 (1.1) 7 (1.1) 4 (2.0)
Other non-frequent pathways 41 (16) 223 (15) 150 (16) 90 (14) 31 (15)
Total 251 (100) 1,485 (100) 936 (100) 632 (100) 201 (100)
Notes: Pathways with a percent frequency of less than 1% were grouped under the category “other non-frequent pathways”. The first drug listing in the treatment pathway 
was considered to be the patient’s initial therapy, and the second drug listing was the prescription after the initial date of COPD diagnosis. all percent values 5.0 were 
rounded up.
Abbreviations: ICs, inhaled corticosteroid; laBa, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; mMRC, modified Medical Research Council; SABA, 
short-acting β2-agonist; saMa, short-acting muscarinic antagonist.
Table 4 Pathways to triple therapy split by exacerbation history
Treatment pathway from date of COPD diagnosis Number of exacerbations at baseline
0 
n (%)
1
n (%)
2
n (%)
3+
n (%)
ICs + laBa → ICs + laBa + laMa 401 (20) 227 (26) 113 (33) 128 (43)
ICs + laBa + laMa 145 (7) 94 (11) 47 (14) 55 (19)
ICs → ICs + laBa → ICs + laBa + laMa 183 (9) 76 (9) 37 (11) 14 (4.7)
none → ICs + laBa → ICs + laBa + laMa 196 (10) 51 (6) 13 (3.8) 8 (2.7)
saBa → ICs + laBa → ICs + laBa + laMa 83 (4.1) 48 (6) 16 (4.7) 14 (4.7)
none → ICs + laBa + laMa 127 (6) 18 (2.1) 4 (1.2) 1 (0.3)
none → laMa → ICs + laBa + laMa 105 (5) 29 (3.4) 8 (2.4) 5 (1.7)
none → ICs → ICs + laBa → ICs + laBa + laMa 96 (4.8) 16 (1.9) 4 (1.2) 2 (0.7)
laMa → ICs + laBa + laMa 67 (3.3) 24 (2.8) 10 (2.9) 6 (2.0)
saBa → ICs → ICs + laBa → ICs + laBa + laMa 51 (2.5) 32 (3.7) 8 (2.4) 0 (0)
saBa + saMa → ICs + laBa → ICs + laBa + laMa 48 (2.4) 28 (3.3) 7 (2.1) 7 (2.3)
saBa → laMa → ICs + laBa + laMa 49 (2.4) 16 (1.9) 7 (2.1) 5 (1.7)
ICs → ICs + laMa → ICs + laBa + laMa 33 (1.6) 22 (2.6) 6 (1.8) 5 (1.7)
ICs → ICs + laBa + laMa 29 (1.4) 8 (0.9) 8 (2.4) 5 (1.7)
ICs + laMa → ICs + laBa + laMa 17 (0.8) 15 (1.7) 9 (2.7) 6 (2.0)
laBa → ICs + laBa → ICs + laBa + laMa 21 (1.0) 12 (1.4) 3 (0.9) 4 (1.3)
none → laBa → ICs + laBa → ICs + laBa + laMa 30 (1.5) 6 (0.7) 2 (0.6) 0 (0)
Other non-frequent pathways 328 (16) 137 (16) 37 (11) 33 (11)
Total 2,009 (100) 859 (100) 339 (100) 298 (100)
Notes: Pathways with a percent frequency of less than 1% were grouped under the category “other non-frequent pathways”. The first drug listing in the treatment pathway was 
considered to be the patient’s initial therapy, and the second drug listing was the prescription after the initial date of COPD diagnosis. all percent values 5.0 were rounded up.
Abbreviations: ICs, inhaled corticosteroid; laBa, long-acting β2-agonist; laMa, long-acting muscarinic antagonist; saBa, short-acting β2-agonist; saMa, short-acting 
muscarinic antagonist.
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where the percentage of TT being prescribed to GOLD A, 
B, and C patients pre-COPD and post-COPD diagnosis 
was similar. One could assume that administration of TT is 
optimal for patients with COPD, because they receive optimal 
bronchodilation plus anti-inflammatory therapy, but to date 
there is no conclusive evidence on the superiority of dual-
bronchodilation with an ICS (TT) over other therapy options, 
in particular in patients at low risk of exacerbations.9,10
We next examined the pathways to TT, with the most com-
mon pathway being ICS plus LABA → TT. This results in the 
issue that once patients are started on ICS plus LABA, the next 
therapeutic option is inevitably TT. It is also key to note that, 
of all the pathways identified with a frequency above 1%, none 
contained dual bronchodilators (LABA plus LAMA) despite 
the LAMA tiotropium being available in the UK in 2002.34 
The recent WISDOM study evaluated the impact of stepping 
patients down from TT to dual bronchodilators. Results from 
this study demonstrated that even in severe and very severe 
COPD patients, the medium-term risk of moderate or severe 
exacerbations was similar between patients who were taken 
off ICS in a stepwise approach, and those who continued to 
receive ICS as part of TT.30 This removal of ICS has also been 
supported in the INSTEAD study where the withdrawal of ICS 
therapy from patients receiving ICS plus LABA, contrary to 
guidelines recommendations, did not have a negative impact 
on lung function and symptoms when compared to patients 
who remained on ICS plus LABA.21,40 There is also real-world 
evidence to further confirm the ability to withdraw ICS, as 
demonstrated by the OPTIMO study.41 These studies indicate 
that many patients with COPD do not need ICS therapy, which 
suggests that the appropriate role of ICS in COPD management 
has not been truly established.40 Furthermore, such studies 
support the possibility of stepping back from ICS-containing 
regimes in patients who do not require them.
When the pathways to TT were further examined accord-
ing to mMRC scores (dyspnea) and lung function impairment, 
it was observed that these had no impact on the pathways to 
TT, with ICS plus LABA → TT being the most common 
pathway to TT. A similar scenario, whereby lung function did 
not influence the prescription of therapies to COPD patients, 
has been previously reported. In the INSTEAD study, patients 
were receiving ICS plus LABA for 3 or more months prior 
to enrolling, despite having a mean FEV
1
 of 64% and having 
no history of exacerbations.21,40 Contrary to mMRC and lung 
function data, exacerbation history was observed to have an 
impact on the prescription pathways to TT, specifically on the 
pathway ICS plus LABA → TT. Overall, this reconfirms the 
point that starting patients with COPD on ICS plus LABA 
inevitably results in the drift to TT, irrespective of severity 
of lung function impairment and breathlessness. While it was 
observed that patients with a previous history of exacerbations 
are justified to be prescribed TT, in this study it was also 
Table 5 Pathways to triple therapy split by lung function grade
Treatment pathway from date of COPD diagnosis Lung function grade (GOLD group)
1
n (%)
2
n (%)
3
n (%)
4
n (%)
ICs + laBa → ICs + laBa + laMa 75 (25) 401 (24) 327 (26) 66 (23)
ICs + laBa + laMa 35 (12) 160 (10) 119 (9) 27 (9)
ICs → ICs + laBa → ICs + laBa + laMa 22 (8) 131 (8) 128 (10) 29 (10)
none → ICs + laBa → ICs + laBa + laMa 21 (7) 124 (8) 96 (8) 27 (9)
saBa → ICs + laBa → ICs + laBa + laMa 12 (4.1) 86 (5) 51 (4.0) 12 (4.2)
none → ICs + laBa + laMa 13 (4.4) 57 (3.4) 64 (5) 16 (6)
none → laMa → ICs + laBa + laMa 9 (3.1) 84 (5) 41 (3.2) 13 (4.5)
none → ICs → ICs + laBa → ICs + laBa + laMa 12 (4.1) 54 (3.3) 45 (3.6) 7 (2.4)
laMa → ICs + laBa + laMa 5 (1.7) 63 (3.8) 30 (2.4) 9 (3.1)
saBa → ICs → ICs + laBa → ICs + laBa + laMa 8 (2.7) 40 (2.4) 39 (3.1) 4 (1.4)
saBa + saMa → ICs + laBa → ICs + laBa + laMa 7 (2.4) 35 (2.1) 41 (3.2) 7 (2.4)
saBa → laMa → ICs + laBa + laMa 8 (2.7) 48 (2.9) 20 (1.6) 1 (0.3)
ICs → ICs + laMa → ICs + laBa + laMa 7 (2.4) 33 (2.0) 20 (1.6) 6 (2.1)
ICs → ICs + laBa + laMa 5 (1.7) 26 (1.6) 16 (1.3) 3 (1.0)
ICs + laMa → ICs + laBa + laMa 6 (2.0) 19 (1.1) 16 (1.3) 6 (2.1)
laBa → ICs + laBa → ICs + laBa + laMa 3 (1.0) 21 (1.3) 10 (0.8) 6 (2.1)
none → laBa → ICs + laBa → ICs + laBa + laMa 5 (1.7) 15 (0.9) 14 (1.1) 4 (1.4)
Other non-frequent pathways 42 (14) 263 (16) 187 (15) 43 (15)
Total 295 (100) 1,660 (100) 1,264 (100) 286 (100)
Notes: Pathways with a percent frequency of less than 1% were grouped under the category “other non-frequent pathways”. The first drug listing in the treatment pathway was 
considered to be the patient’s initial therapy, and the second drug listing was the prescription after the initial date of COPD diagnosis. all percentage values 5.0 were rounded up.
Abbreviations: gOlD, The global initiative for chronic Obstructive lung Disease; ICs, inhaled corticosteroid; laBa, long-acting β2-agonist; laMa, long-acting muscarinic 
antagonist; saBa, short-acting β2-agonist; saMa, short-acting muscarinic antagonist.
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relatively common for patients with no exacerbation history, 
or with low symptoms or protected lung function, to eventu-
ally drift to TT, without being prescribed more appropriate 
therapies like dual bronchodilators. This highlights the need to 
amend behavior and provide better education on how exacerba-
tions in COPD can be avoided and what are the recommended 
therapeutic options for patients with COPD. It should be noted 
though that in the year prior to this study, approximately 14% 
of patients had frequent exacerbations compared with 67% of 
patients who did not experience any exacerbations. The addi-
tion of ICS would only be indicated in a subgroup of COPD 
patients where exacerbations required treatment with systemic 
corticosteroids (with or without antibiotics), not if these exac-
erbations were treated with antibiotics only.42,43 This is similar 
to data from a study by Lange et al44 where approximately 2% 
and 7% of COPD patients had two or more exacerbations a 
year (frequent exacerbators) in COPD GOLD stages 2 and 3, 
respectively. It is important to highlight that, generally, there 
are lower frequencies of frequent exacerbators in primary-
care-based COPD studies (eg, OPCRD) and population-based 
COPD studies (eg, Copenhagen studies and Rotterdam Study) 
when compared with secondary-/tertiary-care-based studies, 
such as the ECLIPSE study (22%, 33%, and 49% in COPD 
GOLD stage 2, 3, and 4, respectively).45
From the observed pathways to TT, it was particularly 
evident that there was extensive overuse of ICS within the 
frequent pathways, especially in patients with no indication 
for ICS. NICE specifically recommends that ICS should be 
given to patients with a FEV
1
,50% and two or more exac-
erbations in the past 12 months.4 ICS is also indicated for 
patients who have asthma and COPD, and for COPD patients 
who are frequent exacerbators.46 Previous studies have also 
reported the inappropriate use of ICS,5,6,12–17 which can add 
unnecessary additional health care costs47 without providing 
any superior efficacy.10,21,29–31 Aside from efficacy and cost 
concerns with the overuse of ICS, there is a safety concern, 
whereby the long-term exposure to ICS can result in several 
side effects which include pneumonia,26 osteoporosis,25 
diabetes,24 cataracts,22 and tuberculosis.23 With respect to 
pneumonia, studies have demonstrated that ICS use was 
associated with a 70% increase in the rate of hospitalization 
for pneumonia27 and a 69% increase in serious pneumonia, 
defined as hospitalization for or death from pneumonia.28 
A recent real-world study by Harries et al32 has indicated 
that despite the increases in prescribing of LABA plus ICS 
combinations in the UK, the rate of COPD hospitalizations 
has not reduced. The high use of ICS could be due to the fact 
that clinicians are more confident in maintaining patients on 
ICS than switching to other therapies,48 along with the fact 
that GOLD always cites ICS first (before LABA and LAMA) 
in the treatment recommendations, which is based on “alpha-
betical order” instead of the most important drug/drugs being 
cited first (long-acting bronchodilators). Additionally, no 
fixed combination dual bronchodilators were available previ-
ously. GOLD recommendations for primary-care patients are 
based on randomized clinical trials and observational studies 
usually performed in secondary and tertiary care, such as 
ELIPSE,49 which may overestimate the occurrence of COPD 
exacerbations, as well as the benefits of ICS.
There are limitations to this study that have to be acknowl-
edged. The data presented here are historical, and the quality 
of the data is dependent on coding used in the clinical records, 
although prescribing and quality outcome framework-related 
data were well recorded. No centralized spirometry was 
carried out so the quality of spirometry could impact on the 
data collected and classification of patients into the relevant 
GOLD groups. Only one-quarter of all patients met entry 
criteria, which could mean that the treatment received by the 
patients in the study was not typical of all patients. GOLD 
categories might not necessarily be the best way to assess 
prescribing practices for COPD patients, given that FEV
1
 is 
a poor guide to future exacerbations, but symptoms, lung 
function, and exacerbations seemed to have little impact on 
prescribing patterns within this study.
Prescription pathways leading to TT in COPD patients 
without asthma highlight the common practice of prescribing 
ICS-containing regimens and overuse of TT, particularly in 
low-risk patients. The results also highlight the relatively 
low prescribing of bronchodilators as first-line therapy. This 
reflects the persistent uncertainties of physicians in prescrib-
ing the most appropriate therapy to patients with COPD, 
and emphasizes that more efforts are required to improve 
education on and the implementation of COPD guidelines 
regarding COPD therapies.
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